Plus Therapeutics is advancing the field of oncology with its innovative approach to targeted radiotherapeutics, specifically designed for rare and difficult-to-treat cancers. The company’s lead candidate, REYOBIQ (rhenium Re186 obisbemeda), utilizes the radioactive isotope rhenium-186 to deliver high-dose radiation directly to tumors, minimizing damage to surrounding healthy tissues. This method addresses the limitations of traditional external beam radiation therapy (EBRT), which often requires lower doses to protect healthy organs and can lead to patient inconvenience due to frequent treatment sessions.
In an exclusive interview, Dr. Marc Hedrick, CEO of Plus Therapeutics, emphasized the precision of their delivery system, which aims to enhance patient outcomes by targeting cancer cells with extreme accuracy. The ongoing ReSPECT clinical trials are pivotal, showing promising results in terms of safety and efficacy, particularly for aggressive CNS cancers like glioblastoma. As the company continues to innovate, the implications for patient care in oncology could be significant, potentially offering a more effective treatment paradigm that reduces the burden of side effects commonly associated with conventional therapies.
Use the database as your supply chain compass →
